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Dedicated to Gabriela Sillero, for her inspirationAbstract T4 RNA ligase catalyzes the synthesis of ATP b,c-
bisphosphonate analogues, using the following substrates with
the relative velocity rates indicated between brackets: meth-
ylenebisphosphonate (pCH2p) (100), clodronate (pCCl2p) (52),
and etidronate (pC(OH)(CH3)p) (4). The presence of pyrophos-
phatase about doubled the rate of these syntheses. Pamidronate
(pC(OH)(CH2–CH2–NH2)p), and alendronate (pC(OH)(CH2–
CH2–CH2–NH2)p) were not substrates of the reaction. Clodro-
nate displaced the AMP moiety of the complex E-AMP in a
concentration dependent manner. The Km values and the rate
of synthesis (kcat) determined for the bisphosphonates as sub-
strates of the reaction were, respectively: methylenebisphospho-
nate, 0.26 ± 0.05 mM (0.28 ± 0.05 s1); clodronate, 0.54 ±
0.14 mM (0.29 ± 0.05 s1); and etidronate, 4.3 ± 0.5 mM
(0.028 ± 0.013 s1). In the presence of GTP, and ATP or
AppCCl2p the relative rate of synthesis of adenosine 5
0,5000-
P1,P4-tetraphosphoguanosine (Ap4G) was around 100% and
33%, respectively; the methylenebisphosphonate derivative of
ATP (AppCH2p) was a very poor substrate for the synthesis of
Ap4G. To our knowledge this report describes, for the ﬁrst time,
the synthesis of ATP b,c-bisphosphonate analogues by an en-
zyme diﬀerent to the classically considered aminoacyl-tRNA
synthetases.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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0,5000-P1,P4-tetra-
phosphate; Ap4G, adenosine 5
0,5000-P1,P4-tetraphosphoguanosine; App-
CCl2p, adenosine 5
0-(b,c-dichloromethylenetriphosphate); AppCH2p,
adenosine 50-(b,c-methylenetriphosphate); AppC(R1)(R2)p, adenosine 5-
-triphosphate derivative of any bisphosphonate; AppC(R1)(R2)ppA,
diadenosine 50,5000-P1,P4-tetraphosphate derivative of any bisphosphonate;
P3, tripolyphosphate; pC(OH)(CH2–CH2–NH2)p, pamidronate or 3-am-
ino-1-hydroxpropylidene-1,1-bisphosphonate; pC(OH)(CH2–CH2–CH2–
NH2)p, alendronate or 4-amino-1-hydroxybutylidene-1,1-bisphospho-
nate; pC(OH)(CH3)p (HEBP), etidronate or ethane-1-hydroxy-1,1-bis-
phosphonate or hydroxyethylidenebisphosphonate; pCCl2p (Cl2MBP),
clodronate or methane-1-dichloro-1,1-bisphosphonate or dichloro-
methylenebisphosphonate; pCH2p (MBP) or methylenebisphosphonate;
pC(R1)(R2)p, any bisphosphonate
*Corresponding author. Fax: +34 91 5854401.
E-mail address: antonio.sillero@uam.es (A. Sillero).
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.09.0261. Introduction
Bisphosphonates are analogs of pyrophosphate in which the
oxygen bridge between the two phosphates is replaced by a
methylene group (–CH2–) [1]. This structure allows a great
number of possible variations, mostly by changing the two lat-
eral chains on the carbon atom. As happens with the amino
acids (which also have diﬀerent structures on the common
basis of an a-amino acid) each bisphosphonate, depending
on the nature of the attached moieties can be classiﬁed by sev-
eral criteria and has its own physicochemical and biological
properties [2].
Bisphosphonates were employed to prevent scaling in water
installations due to their ability to inhibit calcium carbonate
precipitation [1]. Their use in the treatment of osteoporosis is
based both on empirical clinical grounds and on experimental
approaches. Being the osteoporosis an insidious disease, the
beneﬁcial eﬀects of bisphosphonates are not rapid and require
prolonged periods of medication and statistical and systematic
studies to decide on the worthiness of each treatment. It is
known that bisphosphonates bind to the hydroxyapatite bone
mineral surfaces and deposit on the remodeling zones of the
bone where due to an acidic local medium are absorbed by
osteoclasts, diminishing their viability [3]. Their deleterious ef-
fects are in part due to their ability to generate bisphosphonate
derivatives of ATP [4–8] and to their inhibitory eﬀect on the
mevalonate pathway and on the synthesis of cholesterol [9–
13]. However, many unknowns still prevail on their molecular
mechanism of action.
The work presented below stems from the following two
points:
1. Based on previous studies with aminoacyl-tRNA syntheta-
ses and on the noxious eﬀects of bisphosphonates in Dic-
tyostelium discoideum it is thought that bisphosphonates
are incorporated into analogs of ATP by the back reaction
catalyzed aminoacyl-tRNA synthetases [4–8].
EþATPþAa$ EAaAMPþ PPi ðaÞ
EAaAMPþ pCH2p$ EþAaþAppCH2p ðbÞ
2. In 1990 [14] we suggested that the transfer of AMP to other
compounds with terminal phosphates catalyzed by the
aminoacyl-tRNA synthetases was but a particular case of
a more general type of reactions that could be carried out
by the AMP-forming ligases and by some transferases. This
proved to be the case for a number of such enzymes [15]. In
line with this, the results presented below show that T4
RNA ligase uses very eﬀectively some bisphosphonates asblished by Elsevier B.V. All rights reserved.
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toxic derivatives of ATP. In our view this ﬁnding may oﬀer
a more general perspective on the eﬀect of bisphosphonates
at the cellular level.2. Materials and methods
2.1. Materials
Bisphosphonates used: methylenebisphosphonate, pCH2p (MBP)
(Cat. No. 274291) and etidronate, pC(OH)(CH3)p (HEBP) (Cat. No.
P5248) were from Sigma; clodronate, pCCl2p (Cl2MBP) (Cat. No.
233183), pamidronate, pC(OH)(CH2–CH2–NH2)p, (Cat. No. 506600)
and alendronate, pC(OH)(CH2–CH2–CH2–NH2)p (Cat No: 126855)
were from Calbiochem. Sodium tripolyphosphate, P3 (Cat. No.
5633) was from Sigma. [a-32P] ATP (3000 Ci/mmol) was from Amer-
sham. Shrimp alkaline phosphatase (EC 3.1.3.1) was from Roche Ap-
plied Science. T4 RNA ligase was from the following sources: Roche
Applied Science (1449478, lot No. 85123921), BioLabs (M0204S, lot
No. 34; Promega (M105A, lot No. 21004402) with speciﬁc activities
of 3500, 12000, and 5500 U/mg, respectively. One unit (U) is the
enzyme activity required to catalyze the formation of 1 nmol
[5 0-32P]rA12–18 from [a-
32P] ATP into a phosphatase-resistant form in
30 min at 37 C. Electrophoresis on polyacrylamide gels, in the pres-
ence of SDS showed a unique band with an apparent molecular mass
of 43.5 kDa. The preparations from BioLabs and Promega (but not
from Roche) contained an ATPase activity that, in the course of the
reaction, produced ADP in appreciable amounts (see Fig. 4, lane 2).
TLC silica-gel ﬂuorescent plates were from Merck. Radioactively
labeled nucleotides were quantiﬁed with the help of an InstantImager
(Packard Instrument Co.) HPLC was carried out in a Hewlett–Pack-
ard chromatograph (model 1090) with a diode array detector. The
Hypersil ODS column (4.6 · 100 mm) was from Agilent Technologies.2.2. T4 RNA ligase–AMP complex formation
The reaction mixture (0.02 ml) contained 50 mM Tris/HCl (pH 7.4),
1 mM dithiothreitol (DTT), 5 mM MgCl2, 10 lM (0.1 lCi) [a-
32P]
ATP, 0.02 U of desalted pyrophosphatase and clodronate, as indicated.
The formation of the E-AMP complex was initiated by addition of 2 U
of T4 RNA ligase (Roche). After 15 min incubation, reactions were
stopped with 6.5 ll of concentrated SDS sample buﬀer (0.25 M Tris/
HCl (pH 6.8), 8% SDS, 40% glycerol, 240 mM dithiothreitol, 0.005%
bromophenol blue). The mixtures were heated at 90 C for 3 min and
6-ll aliquots loaded onto a 12% denaturing polyacrylamide gel.Fig. 1. Displacement of the AMP moiety of the T4 RNA ligase-
adenylyl complex by clodronate. (A) The enzyme was incubated with
[a-32P] ATP in the absence or presence of increasing concentrations of
clodronate as indicated, and subjected to SDS–PAGE as described in
Section 2. The relevant portion of the autoradiogram is shown. The
size (in kDa) of coelectrophoresed marker proteins are indicated by the
arrow at the left. (B) The residual (%) adenylylated enzyme (E-AMP)
in the presence of increasing concentrations of clodronate was
quantiﬁed in an InstantImager.2.3. Synthesis of bisphosphonates derivatives of ATP
In the course of these experiments, we were compelled to modify the
assay of T4 RNA ligase. Initially the enzyme used was from Roche;
when most of the experiments of this work had been performed, Roche
discontinued to sell this ligase, and we were forced to get the enzyme
from other sources: BioLabs or Promega. The main results obtained
with those preparations were similar to that obtained with the enzyme
from Roche, except for the presence of a strong ATPase activity (trans-
forming ATP to ADP), that interfered in the assays when low concen-
trations of [a-32P] ATP were used. After several unsuccessful attempts
to inhibit this ATPase activity (with ﬂuoride) we found that the addi-
tion of an ATP regenerating system (pyruvate kinase and phospho-
enolpyruvate) to the reaction mixtures was adequate to overcome
this diﬃculty. Accordingly, with the enzyme from Roche, the reaction
mixtures contained 50 mM Tris/HCl (pH 7.4), 1 mM DTT, 5 mM
MgCl2, 1 U/ml of desalted pyrophosphatase, T4 RNA ligase, ATP
and bisphosphonates as indicated. The assays performed with enzyme
from BioLabs or from Promega were additionally supplemented with
1 mM phosphoenolpyruvate and 0.2 U pyruvate kinase. When re-
quired the T4 RNA ligase was diluted in 50 mM Tris/HCl (pH 7.4),
10 mM DTT and 0.05% bovine serum albumin. A molecular mass of
43.5 kDa was considered to calculate the concentration of the enzyme.
After incubation at 30 C the reaction mixtures were analyzed by one
of the following methods.
TLC. The reaction mixtures (0.02 ml) contained 0.02 mM [a-32P]
ATP (0.2 lCi). Aliquots of 1.5-ll of the reaction mixtures were spot-
ted on silica gel plates and developed for 90 min in dioxane:ammo-
nium hydroxide:water (6:1:6 or 6:1:7, by volume, as indicated).Radioactivity was measured by autoradiography and/or with an
InstantImager.
HPLC. The reaction mixtures (0.05 ml) contained 0.3 mM ATP.
After the indicated times of incubation, 15-ll aliquots were transferred
into 0.09 ml of water and kept at 95 C for 1.5 min.
Aliquots of 0.05 ml were analyzed by HPLC as previously described
[16].3. Results and discussion
3.1. Formation of the E-AMP complex and its reaction with
clodronate (pCCl2p)
Formation of an E-AMP complex, migrating on SDS/PAGE
in a position corresponding to a molecular weight of around
45 kDa, was observed when T4 RNA ligase (Roche) was incu-
bated with [a-32P] ATP (Fig. 1). When clodronate was added
to the reaction mixtures, the AMP moiety of the complex
was displaced by this bisphosphonate, in a concentration
dependent manner, similarly as occurred with P3 [16].
3.2. Relative eﬃciency of methylenebisphosphonate, clodronate,
etidronate, tripolyphosphate, pamidronate, or alendronate
as substrates of the reaction. Inﬂuence of pyrophosphatase
Tripolyphosphate, clodronate, methylenebisphosphonate, or
etidronate were added to a ﬁnal concentration of 1 mM to
reaction mixtures containing 0.02 mM [a-32P] ATP. Samples
were taken from the reaction mixtures at diﬀerent times of
incubation and subjected to TLC. This experiment was
repeated twice with the enzyme from Roche and twice with
the enzyme from BioLabs. The results obtained were similar,
in spite of the contaminant ATPase activity present in the
enzyme from BioLabs. One representative experiment (using
the last enzyme) is depicted in Fig. 2. The relative rate of
velocities obtained for methylenebisphosphonate, clodronate,
etidronate, and tripolyphosphate in the synthesis of the corre-
Fig. 2. Tripolyphosphate (P3), clodronate (pCCl2p), methylenebispho-
sphonate (pCH2p), and etidronate (pC(OH)(CH3)p) as substrates of
the reaction. The reaction mixtures contained 0.02 mM [a-32P] ATP,
1 mM bisphosphonates or P3 as indicated, and 0.04 U of enzyme from
BioLabs; other components as in Material and methods. At diﬀerent
times of incubation (3, 6, 12, and 20 min) aliquots were spotted on
TLC plates, developed with dioxane:ammonium hydroxide:water
(6:1:7) and subjected to autoradiography. The ﬁgure shows the result
obtained after 12 min incubation.
Fig. 3. Characterization of AppCCl2p. A reaction mixture (0.12 ml)
containing 15 U T4 RNA ligase (from Roche), 0.3 mM ATP and
4 mM clodronate was incubated until complete transformation of ATP
into AppCCl2p and an aliquot analyzed by HPLC as described (B).
The rest of the reaction mixture was treated with 2 ll (2U) of shrimp
alkaline phosphatase (AP) for 1 h, and an aliquot analyzed by HPLC
(C). The added phosphatase was denatured by heating at 90 C for
6 min and thereafter the reaction mixture was treated with snake
venom phosphodiesterase (SVP) (D), and treated again with AP (E).
The content of ATP of the reaction mixture before addition of T4
RNA ligase is shown in (A).
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tively. In our hands, pamidronate and alendronate were not
substrates of the reaction (result not shown).
The inﬂuence of the addition of pyrophosphatase was as-
sayed in reaction mixtures containing methylenebisphospho-
nate or clodronate: in both cases the ratio of the velocities
obtained in the presence and absence of pyrophosphatase
was around 2 (result not shown).
3.3. Km values determination for clodronate, methylenebis-
phosphonate, and etidronate
The assays to calculate the Km values for these bisphospho-
nates in the reaction
EþATPþ pCðR1ÞðR2Þp! AppCðR1ÞðR2Þpþ Eþ PPi
were carried out in the presence of a ﬁxed concentration of
[a-32P] ATP (0.02 mM) or 0.3 mM non-radioactive ATP, using
the TLC or HPLC methods, respectively. Other conditions as
described in Section 2. The range of bisphosphonate concentra-
tions used in the assay, the Km values and the rate of synthesis
(kcat) determined were, respectively: clodronate, range: 0.1–1.5
mM; 0.54 ± 0.14 mM (0.29 ± 0.05 s1); methylenebisphospho-
nate, range: 0.1–1.5 mM; 0.26 ± 0.05 mM (0.28 ± 0.05 s1);
etidronate, range 1–6 mM; 4.3 ± 0.5 mM (0.028 ± 0.013 s1).
For comparison, the Km and kcat values calculated for P3 in
the synthesis of p4A were: 1.26 ± 0.09 mM and 0.23 ±
0.04 s1, respectively [16]. The above values were determined
by Lineweaver–Burk analysis and represent the mean and stan-
dard deviation of at least four determinations.
3.4. Characterization of AppCCl2p
Although we have assumed AppCCl2p as the expected prod-
uct to be synthesized in the presence of ATP, clodronate, and
T4 RNA ligase, the validation of such structure was conﬁrmed
by treatment with alkaline phosphatase and snake venom
phosphodiesterase. As shown in Fig. 3, the presumptive
AppCCl2p was resistant to phosphatase, and yielded adenosineas the only UV absorbing product after consecutive treatment
with phosphodiesterase and phosphatase.
3.5. Bisphosphonate, and/or their ATP derivatives, as substrates
or inhibitors of some of the reactions catalyzed by T4 RNA
ligase
In these experiments the following reactions were considered:
EþATP$EAMPþPPi ðcÞ
EAMPþGTP!Ap4GþE ðdÞ
EþATPþpCðR1ÞðR2Þp!AppCðR1ÞðR2ÞpþEþPPi ðeÞ
EþAppCðR1ÞðR2ÞpþGTP!Ap4GþpCðR1ÞðR2ÞpþE ðfÞ
EþAppCðR1ÞðR2ÞpþAppCðR1ÞðR2Þp
!AppCðR1ÞðR2ÞppAþpCðR1ÞðR2ÞpþE ðgÞ
EþAppCðR1ÞðR2ÞpþPPi!ATPþpCðR1ÞðR2ÞpþE ðhÞ
where pC(R1)(R2)p is any bisphosphonate; AppC(R1)(R2)p
and AppC(R1)(R2)ppA are the corresponding ATP or Ap4A
derivatives.
Fig. 4. Synthesis of ATP b,c-bisphosphonate analogues and Ap4G
catalyzed by T4 RNA ligase. (A) The enzyme was incubated for 30 min
in the presence of radioactive ATP and the bisphosphonates indicated
in the upper part of the ﬁgure (lanes 4–7); a control without enzyme
(lane 1) and controls without bisphosphonates (lanes 2 and 3) were
carried out in parallel; all the reaction mixtures (except that in lane 2)
contained the ATP regenerating system. The illustrations in B–D were
obtained after incubation of the reaction mixtures shown in A (lanes 2–
7) with 2 mM GTP for 15, 30, and 60 min, respectively. The nature of
the radioactive spots are indicated at both sides of the ﬁgure. Analysis
of the reaction mixtures were performed by TLC and developed with
dioxane:ammonium hydroxide:water (6:1:6) as indicated in Section 2.
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GTP the T4 RNA ligase catalyzed the synthesis of Ap4G in
two steps: formation of the E-AMP complex and transfer of
the AMP moiety of the complex to GTP (reactions (c) and
(d)), respectively [16]. As shown above, methylenebisphospho-
nate and clodronate (but not alendronate or pamidronate) re-
acted with ATP to synthesize the corresponding derivatives,
AppCH2p and AppCCl2p, respectively (reaction (e)). We won-
dered whether these derivatives, once formed in vitro: (i) could
behave as ATP to generate the E-AMP complex and (ii) could
serve as substrates for the synthesis of Ap4G (reaction (f)) or
even AppC(R1)(R2)ppA (reaction (g)).
For that purpose the following experiment was set up
(Fig. 4A–D). In A, the enzyme was incubated in the presence
of ATP, a regenerative ATP system and the bisphosphonate
indicated (Fig. 4A, lanes 4–7). One control without enzyme
(Fig. 4A, lane 1) and two control reactions (with no added bis-
phosphonate) were carried out in parallel, in the absence
(Fig. 4A, lane 2) or in the presence of the ATP regenerating
system (Fig. 4, lane 3). After 30 min incubation, the following
results were obtained (Fig. 4A): (i) the ATP regenerating sys-
tem was very eﬀective (compare the amount of ADP in
Fig. 4A, lanes 2 and 3); (ii) complete conversion of ATP into
the corresponding ATP bisphosphonate derivative were ob-
tained in the presence of methylenebisphosphonate and clodr-
onate (Fig. 4A, lanes 4 and 5) but not in the presence of
alendronate or pamidronate (Fig. 4A, lanes 6 and 7) where,
as in the absence of bisphosphonates (Fig. 4A, lane 3), similar
small amounts of AMP and Ap4A were formed in both cases,
showing that alendronate or pamidronate were neither sub-
strates of the enzyme nor inhibitors of the synthesis of Ap4A
(Fig. 4A, compare lanes 3, with lanes 6 and 7).
After 30 min incubation, and in order to promote the poten-
tial synthesis of Ap4G the reaction mixtures were supple-
mented with GTP to a ﬁnal concentration of 2 mM and
further incubated for 15, 30, and 60 min (Fig. 4B–D, respec-
tively). As expected [16], an important transformation of
ATP into Ap4G (reaction (d)) was obtained in the absence of
bisphosphonates and in the presence of an ATP regenerating
system (Fig. 4B–D, lanes 3). The synthesis of Ap4G was evi-
dent after 15 min incubation (Fig. 4B, lane 3), with practically
complete transformation of ATP into Ap4G + AMP after
60 min incubation (Fig. 4D, lane 3). The methylene derivative
of ATP remained almost unaltered even after 60 min incuba-
tion with GTP (Fig. 4B–D, lanes 4), showing that this ATP
analogue (AppCH2p) was hardly substrate for the synthesis
of Ap4G. In contrast, the clodronate derivative of ATP
(AppCCl2p) (Fig. 4B–D, lanes 5), synthesized Ap4G, in the
presence of GTP (reaction (f)), at a rate of 2.6 nmoles/mg/
min, about 33% of that obtained in the presence of ATP
(i.e., in the absence of bisphosphonate) (compare Fig. 4B–D,
lanes 3 and 5). The presence of alendronate or palmidronate
in the reaction mixture did not alter appreciably the rate of
synthesis of Ap4G (compare in Fig. 4B–D, lane 3 with lanes
6 and 7), showing that they were not inhibitors of that syn-
thesis.
In a similar experiment, T4 RNA ligase was incubated for
30 min in the presence of radioactive ATP, clodronate, or
methylenebisphosphonate until complete transformation of
ATP into the corresponding bisphosphonate derivatives,
AppCCl2p or AppCH2p (results not shown). Thereafter the
reaction mixtures were supplemented with 2 mM PPi (ﬁnalconcentration) and further incubated for 15, 30, 60, and
120 min. The results were similar to those shown in Fig. 4: in
the presence of PPi, the bisphosphonate derivatives AppCCl2p
and AppCH2p synthesized ATP (reaction (h)) at a rate of 4.0
and 0.6 nmoles/mg/min, respectively (results not shown).
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The aim of this work was to examine whether the synthesis
of bisphosphonate derivatives of ATP could be carried out by
ligases other than the well-established aminoacyl-tRNA syn-
thetases. The results here presented show that T4 RNA ligase
uses methylenebisphosphonate, clodronate and, to a much les-
ser extent, etidronate, but not alendronate nor pamidronate as
substrates for the synthesis of the corresponding ATP deriva-
tives. This ﬁnding seems to support the view that some
non-nitrogen-bisphosphonates are incorporated into toxic bis-
phosphonates derivatives of ATP. This conclusion was reached
with the use of aminoacyl-tRNA synthetases [3,5–7,11,17] and
is here conﬁrmed with T4 RNA ligase. In contrast, nitrogen-
containing bisphosphonates, do not seem to incorporate into
ATP derivatives but do interfere with the mevalonate pathway
[3,9,11,13,18] by inhibiting farnesylpyrophosphate synthase
[12,18]. The reason for the diﬀerent behavior of bisphospho-
nates, depending on the occurrence of a nitrogen atom in its
molecule, is currently unknown.
Since some aminoacyl-tRNA synthetases catalyze the syn-
thesis of bisphosphonate derivatives of ATP, the possibility
that the syntheses here reported were due to an aminoacyl-
tRNA synthetase present as a contaminant in the commercial
preparations of T4 RNA ligase, was contemplated. This possi-
bility was ruled out, since cytidine 3 0,5 0-bisphosphate, a speciﬁc
inhibitor of T4 RNA ligase [16,19] strongly inhibited the syn-
thesis of the ATP derivative of clodronate. In addition the fol-
lowing amino acids: asparagine, aspartate, glycine, histidine,
lysine, phenylalanine, or serine, substrates of the Type II sub-
class of aminoacyl-tRNA synthetases [3] did not stimulated,
but rather inhibited, the synthesis of the ATP clodronate deriv-
ative catalyzed by T4 RNA ligase (results not shown).
In our view and related with bisphosphonates, the conclu-
sions reached with a certain enzyme, cannot be extrapolated
to other enzymatic systems: methylenebisphosphonate was a
good substrate for the synthesis of both its ATP (reaction (e))
and its Ap4A derivatives (reaction (g)) in the aminoacyl-tRNA
synthetases system [17]. However, with T4 RNA ligase, meth-
ylenebisphosphonate is a good acceptor of AMP (reaction
(e)) but its ATP derivative was a bad acceptor of GTP (reaction
(f)) and of PPi (reaction (h)). Based on that, we think that the
knowledge of the biochemical bases of the mechanism of action
of bisphosphonates is still rather scanty and could depend on
the enzymatic system considered. We are at present engaged
in a systematic study of the eﬃciency of other ligases to use dif-
ferent bisphosphonates for the synthesis of ATP derivatives.
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